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Summary: A novel quantitative liver function test is described which is based on monoethylglycinexylidide
(MEGX) formation after lidocaine bolus injection. Following the administration of small single doses of
lidocaine hydrochloride (l mg/kg), monoethylglycinexylidide serum concentration-time curves were determined
by a novel highly sensitive fluorescence Polarisation immunoassay (FPIA) in healthy volunteers, liver donors
and patients with liver cirrhosis. The FPIA allowed rapid and reliable monoethylglycinexylidide determinations
in serum and urine (between-days coefficient of Variation: < 10.3%, recovery: 80-113%). Monoethylglyci-
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nexylidide concentrations measured by FPIA in 32 serum samples from patients correlated well those
determined by HPLC. The monoethylglycinexylidide concentration in serum determined 15min after a
lidocaine bolus injection proved to be a highly sensitive and specific indicator of hepatic dysfunction. Average
monoethylglycinexylidide concentrations in serum obtained 15 min after lidocaine injection were substantiälly
lower in patients with liver cirrhosis than in healthy volunteers. The average monoethylglycinexylidide
concentrations in serum were also substantiälly lower in liver donors with ballooning or fatty changes of
hepatocytes than in donors without relevant alterations of liver histology. By means of 'monoethylglycinexy-
lidide formation in the liver donors, primary function of the transplanted liver was correctly predicted in
32/37 cases and initial non-function in 4/6 cases.
Introduction
In the past few years, liver transplantation has gained
increasing importance for the treatment of liver failure
in acute and chronic liver disease. This development
has created a great demand for suitable tests for the
assessment of liver function particularly in liver al-
lograft donors and recipients.
Assessment of liver function is essential in potential
liver donors in order to avoid transplantation of or-
gans with a high risk of initial non-function. Macro-
scopic appearance, clinical chemical analyte determi-
nations (e. g. aspartate aminotransferase, bilirubin)
and common quantitative liver function tests (e. g.
indocyanine green (1) or galactose (2) elimination)
often fail to provide sufficient prognostic Information
(3, 4). In a previous study Forrest et al. (5) reported
that in patients with chronic liver disease elimination
of lidocaine was much more affected than that of
antipyrine and paracetamol. Therefore these authors
concluded that the half-life of lidocaine is a highly
sensitive indicator of hepatic dysfunction. Recently it
has been suggested that the formation kinetics of the
lidocaine metabolite monoethylglycinexylidide
(MEGX) could be used in the evaluation of liver
function (6).
Lidocaine is metabolized by the liver and only about
3% of the dose is excreted äs intact drug in the urine
over 24 hours (7). Monoethylglycinexylidide (fig. 1)
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Fig. l . Structural formulae of lidoeaine and monoethylglyci-
nexylidide (MEGX).
is formed from lidocaine via oxidative N^deethylation
by the hepatic cytochrome P-450 System (8). Mono-
ethylglycinexylidide, which is further metabolized to
glycinexylidide and 4-hydroxy-2,6-xylidine, is found
only in small quantities (about 4% of the lidocaine
dose) in the urine (7). The pharmacokinetics and
pharmacodynamics of monoethylglycinexylidide have
recently been studied in healthy subjects (9).
The present study was designed to investigate the
clinical usefulness of monoethylgiycinexylidide for-
mation kinetics for the assessment of liver function.
For this purpose monoethylglyeinexylidide serum
concentration-time curves were determined by use of
a novel highly sensitive fluorescence Polarisation im-
munoassay (FPIA) in healthy volunteers, liver donors
and patients with liver cirrhosis. A further aim of the
study was to assess the äccuracy of the FPIA by
comparison with HPLC. Monoethylglycinexylidide
concentrations in serum following lidocaine bolus in-
jection were studied for possible correlation with the
morphological features of liver grafts.
Materials and Methods
Study design
Venous blood "was taken from 16 healthy volunteers and 13
patients with histologically confirmed liver eirrhosis at 2, 5,10,
15, 20, 30, 60, 120, 180, 240 and 300 min after bolus injection
of l mg/kg lidocaine hydrochloride (Xylocaine® solution 20 g/l;
Astra Chemicals, Wedel, F. R. G.). Durrag the fürst hour after
lidocaine injection the healthy volunteers and the patients were
in a recumbent position. Urine samples were collected at inter-
vals of 3 h over a period of 24 h. In addition, the 15 min
monoethylglycinexylidide concentrations in serum were deter-
mined in 12 fully rehabilitated liver recipients, who had survived
liver transplantation for l to 12 years. Test subjects participated
in. the study after giving written infonned consent.
In 48 liver donors with confirmed brain death, resülting from
head injury or intracranial haemorrhage, blood was taken be-
fore äs well äs 15, 30 and 60 min after an intravenous lidocaine
(Xylocaine®) bolus iajection (l mg/kg). The investigations on
monoethylglyeinexylidide formation kinetics were part of a
collaborative study on the assessment of donor suitability which
was approved by the local Ethics Comnaittee.
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Fig. 2. Chromatograms of extracts from drug-free human serum (a) and from a serum sample of a patient who had received a
lidocaine bolus injection (b). Peaks: glycinexylidide (1); tocainide, internal Standard (2); monoethylglycinexylidide (3);
lidocaine (4).
Materials
The reagents for the fluorescence Polarisation immunoassay
(FPIA) were provided for investigational use by Abbott Lab-
oratories (North Chicago, U. S. A.). Monoethylglycinexylidide
hydrochloride, lidocaine hydrochloride, glycinexylidide hydro-
chloride, 4-hydroxy-2,6-xylidine hydrochloride and tocainide
.hydrochloride were a generous gift from Astra Alab AB (S d-
ert lje, Sweden). Triethylamine (Fiuka AG, Buchs, Switzerland)
or orthophosphoric acid 85% (E. Merck, Darmstadt, F. R. G.)
were of analytical reagent grade. Acetonitrile (Baker, Gro -
Gerau, F. R. G.) was of HPLC grade. All other chemicals were
purchased from E. Merck (Darmstadt, F. R. G.).
Fluorescence polarisation immunoassay (FPIA)
Monoethylglycinexylidide determinations in serum or urine
were carried out by fluorescence polarisation immunoassay
(Abbott Laboratories, North Chicago, U. S. A.) using the TDx
Fluorescence Polarisation Immunoassay System according to
the instructions of the manufacturer. In a slight modification
of the original procedure (10) calibrators were used, which
contained monoethylglycinexylidide concentrations of 25 to 250
μg/l. Standard Solutions were prepared by dissolving 23.34 mg
monoethylglycinexylidide hydrochloride in 200 ml water (rela-
tive molecular mass of monoethylglycinexylidide: 206.16). One
ml was diluted with water to 100 ml. This solution (1000 μg/l)
was further diluted l + 3, l 4- 4.7, l + 9, l + 19 and l + 39
with monoethylglycinexylidide-free human serum, yielding the
f llowing mon ethylglyeinexylidide concentrations: 250, 175,
100, 50 and 25 μg/l. Pure serum was used s zero calibrator.
Detection limit of fluorescence polarisation immu-
noassay
A series of 20 zero calibrator samples was analysed by fluores-
cence polarisation immunoassay. The 'mean and Standard de-
viation of the observed fluorescence polarisation values were
calculated. The calibration curve was used to determine the
monoethylglycinexylidide concentration which corresponded to
the fhiorescence polarisation obtained by subtraction of the
three^fold Standard deviation from the mean. In aceordance
with a definitipn by Kaiser (11) this value was regarded s the
detection limit of the assay.
High performance liquid chromatography (HPLC)
HPLC was performed by a modification of a procedure de-
scribed by Nation et al. (12). To l ml of serum or Standard in
a glass conical tube were added: 100 μΐ of internal Standard
solution (1.25 mg/1 tocainide in water), 100 μΐ of l mmol/1
NaOH, and 3 ml of ethylacetate. The tubes were shaken me-
chanically for 1min (Multivortex), centrifuged at 1000g for
5min, and the upper (organic) phase was transferred into a
clean glass conical tube. Then 100 μΐ of 0.01 mol/1 HC1 was
added, and the tubes were shaken and centrifuged s described
above. An aliquot of 40 μΐ from the lower (aqueous) phase was
injected into the Chromatograph.
The Chromatographie System consisted of a Hewlett Packard
HP 1090 equipped with an automatic sample injector, a heated
oven compartment, a diode-array-detector, and a 3392 A digital
integrator. Chromatography was performed on a reversed-
phase C8 analytical column (Hypersil-MOS, 5 μπι, 200 χ 4.6
mm I. D.; Hewlett Packard, Waldbronn, F. R. G.)) at an oven
temperature of 40 °C. The diode-array-detector was operated
at 205 nm. The mobile phase was a mixture (30 + 70, by vol.)
of acetonitrile and a solution (pH: 2.4) containing 8.7 mmol/1
orthophosphoric acid plus 7.2 mmol/1 triethylamine. It was
delivered under isocratic conditions at a flow rate of 2 ml/min.
A chromatogram is shown in figure 2. Standards were prepared
by addition of varying known amounts of monoethylglycine-
xylidide to monoethylglycinexylidide-free human serum. Stand-
ard curves were plotted s the metabolite-to-internal Standard
peak height ratio versus the concentration of the Standard
samples. The linear regression iine was calculated by the method
of least squares (fig. 3).
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Fig. 3. Calibration curve for the determination of monoethyl-
glycinexylidide in serum by HPLC. Peak-height ratio is
defined s: height of monoethylglycinexylidide peak/
height of internal Standard peak.
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Stat is t ical analysis
The Statistical evaluation of the results obtained by fluorescence
Polarisation immunoassay and HPLC was based on the stan-
dardised principal component analysis (13) and the significance
of the bias χ — y (paired t-test). Unless stated otherwise mean
values with Standard deviation are given. Monoethylgiycinexyli-
dide concentrations in serum obtained in healthy volunteers
and liver donors 15 min after lidocaine bolus injection were
compared using the unpaired t-test.
Results
Precision of FPIA and HPLC
At monoethylglycinexylidide concentrations in serum
between 26 and 202 μg/l the within series relative
Standard deviations ranged from 2.2 to 10.0% (tab.
1). Spiked human urine samples containing 1000 μg/l
monoethylglycinexylidide showed a satisfactory pre-
cision with this assay (relative Standard deviation:
4.4%). The urine samples were diluted eleven-fold
with TDx System dilution buffer (bovine γ-globulin
in phosphate Buffer) before being assayed. Between-
days relative Standard deviations of single determi-
nations in serum were 4.5 and 10.3% at concentra-
tions of 109 and 59 μg/l respectively. With HPLC the
within series relative Standard deviations of single
determinations in serum ranged from 3.2 to 9.2%
(tab. 1).
Accuracy of FPIA
Average recoveries of monoethylglycinexylidide
added to drug-free human serum are shown in table
2. At monoethylglycinexylidide concentrations in
serum between 20 and 200 μg/l recovery ranged from
80 to 113% and 94 to 107% with FPIA and HPLC
respectively. In spiked urine samples (n = 2) contain-
ing 1000 and 3000 μg/l monoethylglycinexylidide, re-
coveries with FPIA were 112 and 101% respectively.
In addition, monoethylglycinexylidide concentrations
in serum, measured by fluorescence Polarisation im-
munoassay, were compared with those determined by
HPLC. Serum samples from 32 patients receiving
single lidocaine bolus injections were analysed by both
methods. As sh wn in figure 4 b th methods corre-
lated well. The monoethylglycinexylidide concentra^
tions in serum obtained by fluorescence Polarisation
immunoassay were on average about 10% higher than
those determined by HPLC (p < 0.05).
Specificity of FPIA
The specificity of the FPIA was assessed by adding
lidocaine and major metabolites of this compound to
drug-free human serum. No significant eross-reac-
tioiis were found with lidocainej glycinexylidide and
4^hydroxy-2,6-xylidine (tab. 3).
Tab. 1. Precision of FPIA and HPLC for the determination of monoethylglycinexylidide (MEGX) in serum.
FPIA
Precision within series1)
χ3) SD n4)
Precision between days?)
W) SD
HPLC
Precision within series1)
n4) x3)
1) determined with spiked human serum samples
2) determined with diluted contrql serum (Abbott)
3) mean value (x) with relative Standard deviation (SD %)
4) number of contributing values
Tab. 2. The recovery of monoethylglycinexylidide (MEGX) by FPIA and HPLC in serum.
FPIA
Monoethylglycinexylidide
HPLC
Monoethylglycinexylidide
Weighed in Found Recovery Weighed in Found
1) number of contributing values
SD n4)
26
40
76
146
202
10.0
4.5
5.0
1.9
2.2
10
10
10
10
10
59
109
10.3
4.5
15
15
26
54
117
9.2
4.0
3.2
10
10
9
Recovery n1)
20
40
75
150
200
16
45
84
165
225
80
113
112
100
113
10
10
10
10
10
25
50
125
26.2
53.6
117.4
105
107
94
10
10
9
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Fig. 4. Monoethylglycinexylidide serum concentrations s mea-
sured by HPLC and FPIA in samples from patients
(n = 32) receiving single lidocaine bolus injections.
[y = l.lOx -f 0.11; r = 0.924; x(s) = 95.7 (34.5)
y(s) = 105.4 (37.9) jig/L]
Tab. 3. Cross-reactivity of lidocaine and major lidocaine me-
tabolites in serum with the FPIA.
Compound1) mg/12)
Monoethylglycinexylidide (MEGX) 0.03
Lidocaine 43.0
Glycinexylidide 11.0
4-Hydroxy-2,6-xylidine > 1000.0
1) Substances were added to drug-free human serum.
2) Concentration producing a response in the FPIA equivalent
to 0.03 mg/1 monoethylglycinexylidide.
Detection limit
The detection limit fbr monoethylglycinexylidide was
11 μ§/1 with the fluorescence Polarisation immunoas-
say.
Monoethylglycinexylidide concentrations in
serum after lidocaine bolus injection
In figures 5, 6 and 7 the formation and elimination
kinetics of monoethylglycinexylidide are shown for
healthy volunteers* patients with histologically con-
firmed liver cirrhosis and liver doriors after adminis-
tration of single intravenous lidocaine bolus injections
(l mg/kg). To exclude patients with previous lidocaine
therapy, only data from those subjeets with mono-
ethylglycinexylidide predose serum concentrations be-
low the detection limit of the fluorescence Polarisation
immunoassay were included in these figures.
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Fig. 5. Monoethylglycinexylidide concentrations in serum de-
termined in 16 healthy volunteers after a single bolus
injection of lidocaine hydrochloride (l mg/kg). The dot-
ted line marks the detection limit of the FPIA. The
median values (horizontal bars) were used to generate
an averaged concentration-time curve of monoethylgly-
cinexylidide.
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Fig. 6. Monoethylglycinexylidide concentrations in serum de-
termined in 13 patients with liver cirrhosis after a single
bolus injection of lidocaine hydrochloride (l mg/kg).
For further explanation see legend of flg. 5.
There was a rapid increase of monoethylglycinexyli-
dide concentration in serum within the first 15 min
after lidocaine administration in normal subjeets (fig.
5). The highest serum concentrations of this metab-
olite were measured 15 min after lidocaine injection.
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Fig. 7. Monoethylglycinexylidide coricentrations in serum de-
termined in 32 liver donors after a single bolus injection
of lidocaine hydrochloride (l mg/kg). For further ex-
planation see legend of flg. 5.
In one of the healthy subjects only relatively low
monoethylglycinexylidide concentrations were ob-
served. This subject excreted a relatively large amount
of monoethylglycinexylidide within the first three
hours after lidocaine injection (94 g per kg body
weight). In all the other healthy volunteers (n = 15)
tested the average urinary excretion of monoethylgly-
cinexylidide during this period was only 20.7 g per
kg body weight (ränge: 2.0—45.0 g/kg).
In patients with liver cirrhosis the rate of monoethyl-
glycinexylidide formation from lidocaine was sub-
stantially decreased (fig. 6). Therefore the averaged
concentration-time curve observed in these patients
was different from that obtained in healthy subjects.
Within the first 15 minutes only very low serum
concentrations of monoethylglycinexylidide were
found. Maximal serum concentrations of this metab-
olite were observed at about 240 min after lidocaine
injection. In these patients (n = 13) the average uri-
nary excretion of monoethylglycinexylidide within the
first 3 hours after lidocaine administration was only
4.0 g per kg body weight (ränge: 0.2-10.0 g/kg).
In fully rehabilitated liver recipients (n = 12), the 15
min monoethylglycinexylidide concentrations in
serum (median: 97 g/l; ränge: 54—155 g/l) were in
the ränge observed in normal subjects (fig. 5).
In liver donors, the average monoethylglycinexylidide
concentrations in serum, determined 15, 30 and 60
min after lidocain bolus injection, were significantly
(p < 0.05) higher than the corresponding values ob-
tained in normal subjects (fig. 5, 7).
Figure 8 shpws monoethylglycinexylidide concenträ-
tions in serum determined 15 min after i. v. lidocaine
bolus injection in donors with normal liver histology,
donors with altered liver histology, such äs fatty
changes or ballooning of hepatocytes, äs well äs in
patients with histologically confirmed liver cirrhosis.
Monoethylglycinexylidide concentrations in serum
obtained with livers not transplanted becaüse of their
macroscopic appearance are represented äs black tri-
angles. Open diamonds indicate initial non-fünctiön
after transplantation. Boxes delimit the 16th to 84th
300r
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Fig. 8. Monoethylglycinexylidide concentrations in serum de-
termined 15 min after a bolus injection of lidocaine
hydrochloride (l mg/kg) in donors with normal liver
histology, donors with altered liver histology and pa-
tients with liver cirrhosis. Monoethylglycinexylidide
concentrations in serum were determined for:
livers showing initial function following transplantation
( ),
livers showing initial non-function following transplan-
tation (O),
livers not transplanted becaüse of macroscopic appea-
rance ( ),
livers of patients with liver cirrhosis (o).
Boxes delimit the 16th to 84th percentile. The rnedian
is indicated by the horizontal line in each box. The
dotted line marks the detection Jimit of the FPI A.
J. Clin. Chem. Clin. Biochem. / Vol. 25,1987 / No. 12
Oellerich et al.: Monoethylglycinexylidide formation and liver function 851
percentile (68 percent of values). The median is indi-
cated by the horizontal line in each box.
Monoethylglycinexylidide concentrations in serum 15
min after i. v. lidocaine bolus injection were on aver-
age distinctly higher in donors with normal liver his-
tology than in those with ballooning or fatty changes
of hepatocytes and patients with liver cirrhosis. In 37
accepted organs, initial liver function and initial non-
function were correctly predicted by means of mono-
ethylglycinexylidide in 32 cases. Initial non-function
of the liver following transplantation was observed 6
times. In four cases this event was correctly predicted
by means of monoethylglycinexylidide.
Eleven donor organs were not transplanted because
of their macroscopic appearance. Six out of eleven
cases showed normal histology and normal mono-
ethylglycinexylidide formation. In 3/11 cases patho-
logical fmdings of monoethylglycinexylidide and his-
tology were observed. The remaining 2 cases had
normal monoethylglycinexylidide values but patho-
logical histology.
Discussion
The results of our study demonstrate that the de-
scribed fluorescence Polarisation immunoassay is suit-
able for determination of the low monoethylglycine-
xylidide concentrations present in serum after small
lidocaine hydrochloride test doses of l mg per kg body
weight. A comparison of the results determined by
fluorescence Polarisation immunoassay with those ob*
tained by high performance liquid chromatography
showed a satisfactory cörrelation between both meth-
ods (fig. 4).
Our study on monoethylglycinexylidide formation ki-
netics confirms previous reports regarding the de-
pendence of lidocaine elimination on liver function
(5, 14, 15). In general a monoethylglycinexylidide
cpncentration in serum determined 15 min after a
lidocaine bolus injection seems to reflect well the
initial formation rate of this metabolite (fig. 5, 6). So
far, only one case has been encountered, in which the
15 min monoethylglycinexylidide conceiitration in
serum was affected by an unusually high urinafy
excretion of this metabolite.
The monoethylglycinexylidide concentrations in
serum, measured 15 min after lidocaine bolus injee-
tion, were on average significantly higher in liver
donors than in normal subjects (fig. 5, 7). At present
it may only be speculated that this phenomenon is
due to an induction of lidocaine metabolism and/or
an increased hepatic blood flow in donors caused by
other therapeutically administered drugs.
As shown in figure 8 the monoethylglycinexylidide
concentration in serum determined 15 min after a
lidocaine test dose was a highly sensitive and specific
indicator of hepatic damage. Measurement of initial
monoethylglycinexylidide concentrations in serum al-
lowed a satisfactory differentiation between the pop-
ulation of patients with liver cirrhosis and that of
donors with normal liver histology. Monoethylglyci-
nexylidide concentrations observed in donors with less
prominent histological changes showed some overlap
with the concentrations of monoethylglycinexylidide
determined in both groups of donors with normal
histology and patients with liver cirrhosis. More data
are needed to define a meaningful "cut-off value to
distinguish between the presence and absence of liver
damage. So far the "cut-off has been empirically set
at a monoethylglycinexylidide concentration in serum
of 50 §/1, since concentrations below this value were
generally associated with hepatic impairment (4).
Preliminary data on survival rates of recipients of
primary liver transplants indicate that monoethylgly-
cinexylidide formation may provide valuable prog-
nostic Information. A significant difference
(p < 0.005) was observed in survival between recipi-
ents of allografts from donors with monoethylglyci-
nexylidide concentrations in serum above 90 g/l and
those with concentrations of this compound below
this value (16). Donor rating with normal or patho-
logic indocyanine green clearance äs well äs normal
and pathologic galactose elimination capacity, how-
ever, failed to give satisfactory prognostic Informa-
tion. One to twelve years after transplantation, fully
rehabilitated liver recipients showed 15 min mono-
ethylglycinexylidide serum concentrations similar to
those found in healthy volunteers.
Further evidence regarding the usefulness of the de-
scribed approach for the assessment of liver function
was recently obtained in a comparative study with
various established liver function tests (e. g. indocy-
anine green clearance, galactose elimination capacity).
It was demonstrated that a single monoethylglycine-
xylidide serum concentration determined in liver do-
nors 15 min after intravenous administration of a
lidocaine test dose häd a distinctly higher predictive
value for the assessment of primary non-function of
the subsequently transplanted liver than all the other
liver function parameters tested (4).
It appears that certain specific drug-metabolizing
pathways are sensitive to hepatocellular injury. Based
on N-demethylation, for example, an aminopyrine
breath test was developed (17, 18), which permits the
detection of even minor hepatic injuries. In a modi-
fication of this concept we have chosen monoethyl-
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glycinexylidide formation after lidocaine injection äs
indicator of liver function. It has been demonstrated
that monoethylglycinexylidide formation depends
mainly on hepatic cytochroine P-450-mediated N-
deethylation (8, 19). Since the parent drug lidocaine
has an intermediate-high though variable hepatic ex-
traction ratio (20), it has to be expected that the rate
of monoethylglycinexylidide formation may be af-
fected to a certain extent by major changes of hepatic
blood flow. It has to be considered, however, that
according to a study of Huet et al. (20), in patients
with cirrhosis the disposition of lidocaine is scarcely
influenced by hepatic blood flow and becomes limited
by intrinsic clearance. So far, it is not known to what
extent changes in the distribution volume of mono-
ethylglycinexylidide can infhience the 15 min concen-
tration of this substance in serum. From our clinical
experience, however, this factor is unlikely to have a
negative effect on our test results, since a clear-cut
Separation of normal subjects and patients with his-
tologically proven liver cirrhosis was possible by use
of the 15 min monoethylglycinexylidide concentration
in serum.
In a further study with liver donors the results of the
monoethylglycinexylidide test were compared with
those of indocyanine green clearance and galactose
elimination capacity. A differentiation between nor-
mal and pathologic donor liver histology was only
possible with the monoethylglycinexylidide formation
test (16).
Lidocaine at the low doses used in our study appears
to be a safe test compound. It has to be considered,
however, that this substance can produce anaphylactic
reactions (21). For liver donors or recipients, however,
this problem is of relatively low singificance since
these patients are closely monitored at intensive care
units. So far in our study adverse reactions, other
than slight drowsiness in patients with severe hepatic
impairment, were not observed;. rln comparison with
other liver function tests, such äs the aminopyrine
breath test (22) or bromosulphqphthalein test (23),
the risk of serious side effects appears to be consid-
erably löwer with the described lidocaine test.
The fluorescence Polarisation immunoassay is rapid
and easy to perform. A single serum sample from a
patient can be analysed within about 20 min. There-
fore this assay is very convenient for the assessment
of liver quality in potential donors, since the results
can be made available eärly before transplantation.
This aspect is of particular importance beeause his-
tologically and functionally intact organs are often
not transplanted beeause of macroscopic appearance.
In our study we observed that 55% of the livers not
accepted for transplantation beeause of macroscopic
appearance would have been suitable for transplan-
tation according to histology and the described lido-
caine liver function test,
From the results of our study it is concluded that the
analysis of hepatic monoethylglycinexylidide forma-
tion is a promising new approach for rapid assessment
of hepatic function, particularly in liver donors. A
prospective study is currently in progress at our hos^
pital to further investigate the diagnostic and pfog-
nostic value of this test.
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